Atria Investments Inc Buys New Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Atria Investments Inc purchased a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 2,507 shares of the company’s stock, valued at approximately $286,000.

A number of other institutional investors also recently bought and sold shares of the business. Russell Investments Group Ltd. acquired a new position in Vaxcyte in the first quarter valued at approximately $1,288,000. Vanguard Group Inc. lifted its stake in shares of Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares during the period. O Shaughnessy Asset Management LLC acquired a new position in shares of Vaxcyte in the 1st quarter valued at $321,000. American International Group Inc. boosted its holdings in Vaxcyte by 12.2% during the first quarter. American International Group Inc. now owns 52,313 shares of the company’s stock worth $3,574,000 after buying an additional 5,686 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co grew its position in Vaxcyte by 163.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 18,064 shares of the company’s stock valued at $1,234,000 after buying an additional 11,208 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Jefferies Financial Group upped their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Bank of America increased their price target on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Mizuho boosted their price objective on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research report on Tuesday, September 10th. Leerink Partners increased their target price on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $88.54 on Friday. Vaxcyte, Inc. has a one year low of $48.24 and a one year high of $121.06. The business has a fifty day moving average price of $107.89 and a 200 day moving average price of $89.26. The company has a market cap of $11.04 billion, a P/E ratio of -19.25 and a beta of 1.01.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same quarter in the previous year, the company earned ($0.91) earnings per share. As a group, sell-side analysts predict that Vaxcyte, Inc. will post -4.14 EPS for the current fiscal year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 2,366 shares of the firm’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $103.89, for a total value of $245,803.74. Following the completion of the sale, the chief executive officer now directly owns 137,398 shares of the company’s stock, valued at $14,274,278.22. This trade represents a 1.69 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Elvia Cowan sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the transaction, the senior vice president now directly owns 12,723 shares in the company, valued at approximately $1,369,885.41. The trade was a 28.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 102,464 shares of company stock worth $11,455,576 in the last ninety days. Insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.